Staffan Schüberg – CEO, Esteve, Spain
Staffan Schüberg, CEO of Esteve, highlights the restructure of the company as it moves towards its new age of being a truly innovative pharmaceutical company on a global level. Furthermore,…
Research in neuroscience has a longstanding tradition in Spain mostly inspired by Nobel Prize winner Santiago Ramón y Cajal and his disciples, for whom the “Instituto Cajal” (IC) was initially conceived in 1934. Five years later the Spanish Government created the National Research Council under the name of Consejo Superior de Investigaciones Cientificas (CSIC) and the IC became one of the first centers of this new Institution. The IC is one of the two CSIC centers fully devoted to research in Neuroscience. The Institute moved to its present location in downtown Madrid in a building of 4,500 m2 in 1989. Currently the IC houses 25 independent research teams and around 200 staff, with operating costs close to 9 K€/year.
From its inception the Cajal Institute has contributed to the advance in Neuroscience and has hosted and formed many of the neuroscientists working now in the different Spanish research and academic centers. Along almost one century of life, the Institute has become a center of worldwide reputation, building on the important contributions of its founder to the present day. Current staff of the Institute has been selected under a tight competitive system according to the high standards of the CSIC. Presently, the institute is organized in two departments: Functional and Systems Neurobiology, and Cellular, Molecular and Developmental Neurobiology, which intend to agglutinate research in all major areas of neuroscience. The focus of the IC research can be comprised in five major lines:
– Mechanisms of neural specification
– The neuro-vascular unit
– Processing of neural signals (a new line of work in neuro-prosthetics and bioengineering is being planned to be incorporated in the near future to reinforce this section)
– Neuroprotection and regeneration
– Systemic modulators of brain function
Contact information:
Cajal Institute (CSIC)
Avenida Doctor Arce 37
28002 Madrid.
Staffan Schüberg, CEO of Esteve, highlights the restructure of the company as it moves towards its new age of being a truly innovative pharmaceutical company on a global level. Furthermore,…
Sergio Rodriguez, CEO of Pfizer Spain, highlights the strength of the affiliate and the importance for the company in Europe, as well as the key areas that are driving their…
Dr Juan Abarca Cidón, president of HM Hospitales, one of Spain’s leading private health groups, gives insight into the private health sector of the country, its relation to the public…
Damaso Molero, general manager of 3P Biopharmaceuticals, a leading Spanish CDMO, highlights the growth of the company and the need to continuously increase capacity to meet market demands. Furthermore, he…
Dr Antonio Alarco gives his insider take on the future of Spanish healthcare, personalized medicine, and the areas in which Spain needs to improve. Innovation is the best investment;…
Daniel-Anibal Garcia Diego, president of the Spanish Haemophilia Federation (FEDHEMO), discusses the current situation of haemophilia treatment and healthcare coverage in Spain, as well as the unique challenges created by…
Alfonso Beltrán García-Echániz, director of the Spanish Foundation for Innovation and Prospective Health (FIPSE), highlights the foundation’s focus, as a new instrument to foster innovation in Spain, as well as…
Antonio Lopez and Diego Monux, CEO and founding partner of SILO (Science and Innovation Link Office), talk about their niche offering of connecting both the public and private sector, in…
Marieta Jiménez, president and general manager of Merck Spain, highlights her three top priorities: innovation, science and technology, and women’s equality. Furthermore, she gives an overview of the need for…
Inês Correia, general manager of the Iberia affiliate of HRA Pharma, a fast-growing consumer healthcare company and leader in women’s health, discusses her transition to the company and challenges in…
Eduardo Barriga, general manager of Boiron, the homeopathic market leader in Spain, discusses the company’s approach to the Spanish market since he took the position two years ago. Furthermore, Barriga…
Stephen Matlin, CEO of Life Length, highlights the evolution of the company over recent years, especially the establishment of their own laboratories which have allowed them to conduct clinical studies…
See our Cookie Privacy Policy Here